F8 and hemophilia A: It can be assumed that a simpleincrease in the production volume of third-generation biosimilar drugs based onrecombinant FVIII will make it possible to increase the volume of substitutiontherapy for hemophilia A, while the current costs remain unchanged (i.e., toimprove patients’ quality of life and increase their longevity withoutreallocating the limited healthcare resources).